Kurt Hertogs has been trained as a Pharmacist, and holds a PhD in Pharmaceutical Sciences from the Catholic University of Leuven. He started his career at Tibotec – a Belgian start up that was acquired by J&J in 2002 and has held a variety of positions in research and early development. He was actively involved in the discovery and pharmacological profiling of Tibotec’s anti-infectives portfolio (Prezista (TMC114), Intelence (TMC125), Edurant (TMC278), Sirturo (TMC207) and Simeprevir (TMC435). In 2013, Kurt took on the role of Platform Innovation & Incubator Strategy Leader at the Johnson & Johnson Innovation Centre. In this role he developed a strategy for creating early stage incubation initiatives across Europe, in concert with local research institutions, entrepreneurs and investors. Recently, Kurt was appointed Head JLINX – the newest J&J Innovation Company Investment and Incubation Model. In addition, Kurt will be the J&J Innovation Lead at the Beerse Campus.